Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort
about
Accelerated atherosclerosis in patients with SLE--mechanisms and managementUnmet medical needs in systemic lupus erythematosusImmunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndromeProtective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.Management of cardiovascular complications in systemic lupus erythematosus.Current status of lupus nephritis.Lupus nephritis: lessons from murine modelsRenal involvement in autoimmune connective tissue diseases.Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosusN-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythematosusLupus nephritis: an overview of recent findings.Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study.Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.Beyond immunosuppression - challenges in the clinical management of lupus nephritis.Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy.Recent advances in the treatment of lupus nephritis.Case-crossover study design in pharmacoepidemiology: systematic review and recommendations.Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.Pathogenesis and treatment of atherosclerosis in lupus.Lupus nephritis: an update.Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study.The evolving concept of SLE comorbidities.[Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis].Premature coronary heart disease in SLE: can we prevent progression?Predictors of incident proteinuria among patients with SLE.Kallikrein–Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation.Kallikrein-Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation.
P2860
Q26820245-D2A8FB4C-89FB-433A-8CF1-4690532ADBC5Q27005906-B4033AB6-B048-4E85-BF6E-FE63814FBACEQ28071723-9271FC3C-EB1F-4AE2-B5AE-5BC25B85828DQ33455990-92852280-7641-44D5-9D56-F77FDBB35E4FQ33730536-3653F4F5-DE5A-4095-9106-B4B0A5EF1F53Q33882751-C95BC321-6D68-4EEC-A4B7-CD07839A5250Q33998360-0A59630B-757B-49BD-AE9D-4FE5F1B5CC07Q34654954-EE35BEBA-A420-41EB-9911-5324A98B69F3Q35543444-B949061F-8688-420C-89FF-39AE3392F6DEQ35622459-469C44A8-7EF0-46A1-9853-5F24832D02BCQ35867038-BB4C2225-D6D3-445E-BB60-D560FCFB5961Q36157955-B5A0D09B-B4F8-4B4E-8551-20810CDE3EF3Q36302245-3C27A61F-DD52-40A8-95A9-070FE1F26471Q37033345-738F2FDC-3FC0-4702-B137-5FF4A0ED05AFQ37371383-3CE7E0E1-1D9D-4352-93B1-6B32269600D9Q37829385-1797C510-FAC5-4D3E-85A4-BF684DB05669Q37953243-0575F552-8E75-410D-B07A-30AF2F8C7109Q38137002-E1171B51-55B8-4D62-8D52-2837F3291D0FQ38205079-DCB4CA22-A888-4ADD-8118-F736652213A8Q38230699-5785F941-B537-40AF-9D4F-2DCE27897ADBQ38608138-48A60E2F-EC49-4BE9-9508-BB0CF60D2F64Q38909471-7E4BDB77-654C-468E-BA38-F7F34C901070Q39283399-09827B43-561C-4B27-9EC4-C18C56A6D433Q41540102-8C4F01EF-35D0-461D-B9B8-DCBE1DCA3030Q43900414-B0C6CB6F-FD62-4068-948F-FB2FC6F9AE46Q47100353-0AFD3833-DA6B-4C0E-A7A7-EBC5D5DDD66EQ49852055-CF198F19-E07A-4AD4-A025-8652C08F0115Q49884872-4FE76736-2D57-4D84-B396-A47A56868A61
P2860
Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Angiotensin-converting enzyme ...... (LIX): a multiethnic US cohort
@ast
Angiotensin-converting enzyme ...... (LIX): a multiethnic US cohort
@en
Angiotensin-converting enzyme ...... hematosus--results from LUMINA
@nl
type
label
Angiotensin-converting enzyme ...... (LIX): a multiethnic US cohort
@ast
Angiotensin-converting enzyme ...... (LIX): a multiethnic US cohort
@en
Angiotensin-converting enzyme ...... hematosus--results from LUMINA
@nl
prefLabel
Angiotensin-converting enzyme ...... (LIX): a multiethnic US cohort
@ast
Angiotensin-converting enzyme ...... (LIX): a multiethnic US cohort
@en
Angiotensin-converting enzyme ...... hematosus--results from LUMINA
@nl
P2093
P2860
P356
P1433
P1476
Angiotensin-converting enzyme ...... (LIX): a multiethnic US cohort
@en
P2093
G S Alarcón
LUMINA (LIX): a multiethnic US cohort
S Durán-Barragán
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEN208
P577
2008-05-29T00:00:00Z